Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Prognostic value of serial liquid biopsy EGFR mutation monitoring in Hispanic patients with advanced NSCLC treated with osimertinib.

Juan Manuel Garzon-Dangond, Andrés Felipe Cardona, Jairo Andrés Zuluaga et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20761

e20761 Background: The prognostic role of serial circulating tumor DNA (ctDNA) dynamics during osimertinib treatment has b...

Insurance and cost-related access barriers to specialty oral anticancer medications for blood cancers in a nationwide sample of Medicare and commercially insured patients.

Jalpa A. Doshi, Pengxiang Li, Zhi Geng et al. Jun 01, 2026 pp. 11031-11031 10.1200/jco.2026.44.16_suppl.11031

11031 Background: Specialty oral anticancer medications improve survival across blood cancers but may have access challeng...

Conversational AI-assisted exploratory data analysis (CA-EDA): A comparative evaluation of commercial large language models for clinical trial analysis.

Yaacov Lawrence, Yakir Malyanker, Ofer Margalit et al. Jun 01, 2026 pp. 1636-1636 10.1200/jco.2026.44.16_suppl.1636

1636 Background: Conventional analysis of clinical trial data requires statistical expertise, time and effort. Previous AI...

Characterization of the immune infiltrate and the chromatin 3D structure of gastric tumors from Mexican patients.

Luis Alfredo Rendón Bautista, Eduardo Blanco Olais, Aura Stephenson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16145

e16145 Background: Identifying cellular populations within tumors and theirmicroenvironment, along with genome structure c...

Evaluation of drug-drug interactions and progression-free survival in patients with prostate cancer treated with androgen receptor pathway inhibitors using the Drug-PIN software: The DDI-AID, a real-world observational study from the Meet-URO Network.

Fiorenza Santamaria, Stefania Di Girolamo, Sabrina Rossetti et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17019

e17019 Background: Androgen Receptor Pathway Inhibitors (ARPIs) are commonly used in metastatic prostate cancer (mPC). Giv...

Real-world evaluation of the decentralized MSK-ACCESS powered with SOPHiA DDM liquid biopsy assay for comprehensive tumor profiling.

Florian Klemm, Fuad Mohammad, Alex Tuck et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15084

e15084 Background: MSK-ACCESS powered with SOPHiA DDM is a decentralized next-generation sequencing (NGS) assay for circul...

Predicting chemotherapy benefit in premenopausal women with intermediate genomic scores using deep learning.

Arkadi Piven, Yoav Binenbaum, Dvir Aran et al. Jun 01, 2026 pp. 602-602 10.1200/jco.2026.44.16_suppl.602

602 Background: The TAILORx trial demonstrated that adjuvant chemotherapy can be safely omitted in postmenopausal women wi...

Preliminary results of a randomized phase II trial of chidamide plus fulvestrant with or without sintilimab in HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (CISFORT).

Haifeng Li, Qixiang Rong, Riqing Huang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13051

e13051 Background: Chidamide is a subtype-selective histone deacetylase (HDAC) inhibitor that has demonstrated clinical ac...

Erythropoietin receptor (EPOR) expression as an independent prognostic biomarker in clear cell renal cell carcinoma, beyond angiogenesis, hypoxia, and erythropoietin ligand.

Max Jesus Bustillo Orozco, Sophio Kakabadze, Darilis Patricia Palacio Bonill Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16520

e16520 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by dysregulated hypoxia and angiogenesis signa...

Ultra-lightweight deep learning for glioma detection: MobileNet-based MRI classification to enable real-time neuro-oncology deployment.

Mustafa Abrar Zaman, Elangovan Krishnan, Sophia Ahmed et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14085

e14085 Background: Gliomas, the most common CNS tumors, are associated with substantial morbidity and mortality. Magnetic...

Diagnostic yield of percutaneous versus open surgical biopsy for tibial bone lesions: A retrospective review.

Dylan Riley, Danielle Hazime, Samuel P. Alfonsi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23505

e23505 Background: Accurate histologic diagnosis is critical for tibial bone tumors, which are among the most common sites...

Efficacy and safety of continuous intra-arterial cisplatin and recombinant human endostatin combined with systemic chemotherapy in osteosarcoma: A phase II study.

Hongtao Li, Chenliang Zhou, Qingyu Chen et al. Jun 01, 2026 pp. 11523-11523 10.1200/jco.2026.44.16_suppl.11523

11523 Background: Previous studies have demonstrated that preoperative intra-arterial cisplatin infusion elicits a favorab...

The weekend effect in spontaneous tumor lysis syndrome in patients with hematological malignancy: National trends in dialysis utilization, mortality, and resource use in the United States.

Manas Pustake, Shubhangi Deoker, Lakshmi Kattamuri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18632

e18632 Background: Spontaneous tumor lysis syndrome (sTLS) is a rare but highly lethal oncologic emergency. Whether outcom...

Detecting resistant subpopulations by profiling drug response heterogeneity in patient-derived cancer organoids (PDCOs) following first-line treatment.

Ninna Struck Rossen, Kamilla Westarp Zornhagen, Rikke Stausholm Sørensen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15603

e15603 Background: Colorectal cancer (CRC) frequently progresses due to resistance to standard first-line chemotherapy, su...

Decision support for treatment of patients with glioblastoma: A systems biology approach enabled by explainable AI.

Thomas D. Brown, Serdar Turkarslan, Christopher Uhl et al. Jun 01, 2026 pp. 2081-2081 10.1200/jco.2026.44.16_suppl.2081

2081 Background: Glioblastoma (GBM) patients (pts) have median survival of 15 months and 5-year survival <7% with stand...

Targeting tumor–stroma crosstalk with ICAM1 antibody–drug conjugates to enable dual-compartment therapy in ovarian cancer.

Lu Sun, Hanfei Xie, Xiao Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15024

e15024 Background: Antibody–drug conjugates (ADCs) have reshaped the treatment of solid tumors, yet their efficacy in ovar...

Combined safety and efficacy results from three clinical studies evaluating alpha radiotherapy for advanced pancreatic cancer.

Corey Miller, Kim Anh Ma, Magali Lecavalier-Barsoum et al. Jun 01, 2026 pp. 4215-4215 10.1200/jco.2026.44.16_suppl.4215

4215 Background: Pancreatic cancer (PDAC) remains associated with poor prognosis and limited treatment options, particular...

Real-world outcomes of early unfractionated heparin use in NSTEMI patients with acute leukemia and severe thrombocytopenia.

Shanawar Ali Waris, Nanda Krishnan Siva, Shilajeet Ray et al. Jun 01, 2026 pp. 6539-6539 10.1200/jco.2026.44.16_suppl.6539

6539 Background: Current AHA/ACC guidelines provide limited guidance for acute non-ST-segment elevation myocardial infarct...

Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis.

Changchuan Jiang, Jennifer Rider, Panayiotis Dimitrios Kontoyiannis et al. Jun 01, 2026 pp. 2636-2636 10.1200/jco.2026.44.16_suppl.2636

2636 Background: Prior study showed mRNA COVID-19 vaccines can activate innate and adaptive immune pathways and have been...

Efficacy and safety of HLX43 (anti–PD-L1 ADC) in patients with advanced non–small cell lung cancer.

Jie Wang, Jianjun Zhang, Ning Li et al. Jun 01, 2026 pp. 8512-8512 10.1200/jco.2026.44.16_suppl.8512

8512 Background: HLX43 (a PD-L1 ADC) has demonstrated encouraging efficacy with a manageable safety in a phase 1 study. He...

Impact of clonal hematopoiesis on clinical outcomes in patients undergoing CAR T-cell therapy: A systematic review and meta-analysis.

Isabela Diniz, Filipe Luis Vasconcelos Visani, Ellen Blanchard-Cavagis et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19011

e19011 Background: Clonal hematopoiesis (CH) is characterized by the expansion of hematopoietic cell clones harboring soma...

Characterization of extracolonic cancers in individuals with Lynch syndrome: A Canadian population-based cohort.

Ethan Lindgren, Heidi Rothenmund, Pascal Lambert et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22658

e22658 Background: While increased risk of colorectal cancer (CRC) is well established in individuals with Lynch syndrome...

Clinical outcome of Asian and non-Hispanic White patients with colorectal cancer in a NCI-designated cancer center serving a diverse catchment area.

Abhiraj Saxena, Christina Boatwright, Hrithik Kumar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15710

e15710 Background: Traditionally, research on the epidemiology and outcomes in minorities in the United States has primari...

Biologic and clinical implications of HPV genome state variation in oropharyngeal cancers.

Vikram Vasan, Lovely Raghav, Malay Kumar Sannigrahi et al. Jun 01, 2026 pp. 6076-6076 10.1200/jco.2026.44.16_suppl.6076

6076 Background: HPV integration enhances carcinogenesis by ensuring viral DNA retention and increasing E6/E7 expression....

Adjuvant abemaciclib in pN2-3 patients with HR+/HER2− early breast cancer: Real-world outcomes from Moscow centers.

Katerina Grechukhina, Dmitriy Popov, Maria Ivanyuk et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12535

e12535 Background: Adjuvant abemaciclib (adA) plus endocrine therapy (ET) resulted in a statistically and clinically signi...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page